BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,050 filers reported holding BAXTER INTL INC in Q4 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $257,594 | -56.2% | 6,027 | -60.3% | 0.14% | -64.1% |
Q4 2023 | $587,632 | +58.1% | 15,200 | +86.3% | 0.38% | +79.6% |
Q2 2023 | $371,724 | +54.9% | 8,159 | +118.3% | 0.21% | -60.9% |
Q2 2022 | $240,000 | -58.3% | 3,737 | -49.7% | 0.54% | -57.3% |
Q1 2022 | $576,000 | +131.3% | 7,427 | +156.1% | 1.26% | +110.8% |
Q4 2021 | $249,000 | +10.7% | 2,900 | +3.6% | 0.60% | +57.5% |
Q2 2021 | $225,000 | -36.4% | 2,800 | -30.8% | 0.38% | +135.2% |
Q3 2019 | $354,000 | -56.2% | 4,049 | -67.0% | 0.16% | -69.7% |
Q4 2018 | $808,000 | – | 12,275 | – | 0.53% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |